Fetal pulse oximetry

• US 20040116789A1
• Filed: 02/05/2004
• Published: 06/17/2004
• Est. Priority Date: 01/28/2000
• Status: Active Grant

• Current Assignee: The General Hospital Corporation (Mass General Brigham, Inc.), Tufts University
• Original Assignee: Tufts University
• Inventors: Boas, David Alan, Zourabian, Anna
• Granted Patent: US 7,047,055 B2
• Time in Patent Office: Days
• US Class Current: 600/338
• CPC Class Codes: A61B 5/14542 for measuring blood gases A61B5/14551 takes precedence
• CPC Class Codes: A61B 5/1464 specially adapted for foetal tissue
• CPC Class Codes: A61B 5/4362 Assessing foetal parameters
• CPC Class Codes: A61B 5/7257 using Fourier transforms

Abstract

A fetal blood pulse oximetry method and apparatus using a first wavelength of light at about 655 to 705 nm and a second wavelength of light at about 820 to 900 nm. Measurements are taken through a mother'"'"'s abdomen. Processing is performed to extract absorption information related to fetal arterial blood with calculation of fetal oxygen saturation from the extracted data.

Claims

1. A method of determining the oxygen saturation of fetal blood, the method comprising

emitting light of a first wavelength onto the abdominal surface of a pregnant mammal over time;

emitting light of a second wavelength onto the abdominal surface of the preganant mammal over time, wherein the second wavelength is different from the first wavelength;

detecting the intensity of light scattered by fetal and maternal arterial blood at the first wavelength and light scattered by fetal and maternal arterial blood at the second wavelength over time, wherein the time of detection is sufficient to record at least one fetal heart beat and at least one maternal heart beat;

converting the detected light into electronic signals;

processing the electronic signals to separate maternal and fetal contributions to the electronic signals;

removing the contributions to the electronic signals generated by maternal arterial blood;

measuring the absorption of light at the first and second wavelengths by fetal arterial blood; and

calculating the oxygen saturation of the fetal arterial blood from the measured absorption of light over time.

2. The method of claim 1, wherein the first wavelength is about 655-705 nm.

3. The method of claim 1, wherein the first wavelength is about 700 nm.

4. The method of claim 1, wherein the second wavelength is about 820-910 nm.

5. The method of claim 1, wherein the second wavelength is about 830 nm.

6. The method of claim 1, wherein the electronic signals are processed using a Fourier transform.

7. The method of claim 1, further comprising

emitting light of a third wavelength, wherein the third wavelength is different from each of the first and second wavelengths;

detecting the intensity of light scattered by fetal and maternal arterial blood at the third wavelength; and

measuring the absorption of light at the third wavelength.

8. The method of claim 7, further comprising

emitting light of a fourth wavelength, wherein the fourth wavelength is different from each of the first, second, and third wavelengths;

detecting the intensity of light scattered by fetal and maternal arterial blood at the fourth wavelength; and

measuring the absorption of light at the fourth wavelength.

9. The method of claim 1, further comprising removing the contributions to the signals generated by light that never passes through fetal tissue.

10. A fetal pulse oximeter comprising

a first light source emitting light at a first wavelength;

a second light source emitting light at a second wavelength, wherein the second wavelength is different from the first wavelength;

one or more photodetectors suitable for detecting light at the first wavelength and light at the second wavelength, the photodetector capable of distinguishing light at the first wavelength from light at the second wavelength;

a probe configured to engage an abdominal surface of a pregnant mammal, the probe coupling the first and second light sources to the photodetector at a substantially fixed position when the probe is engaged to the abdominal surface, and

a processor configured to (1) process the electronic signals generated by the photodetectors in response to detection of light at the first and second wavelengths, (2) remove the contributions to the signals generated by maternal arterial blood, (3) determine the absorption of light at the first and second wavelengths by fetal arterial blood, and (4) calculate the oxygen saturation of the fetal arterial blood from the absorbed light over time.

11. The oximeter of claim 10, wherein the first wavelength is about 655-705 nm.

12. The oximeter of claim 10, wherein the first wavelength is about 700 nm.

13. The oximeter of claim 10, wherein the second wavelength is about 820-910 nm.

14. The oximeter of claim 10, wherein the second wavelength is about 830 nm.

15. The oximeter of claim 10, wherein the processor processes the electronic signals using a Fourier transform.

16. The oximeter of claim 10, further comprising

a third light source emitting light of a third wavelength, wherein the third wavelength is different from each of the first and second wavelengths;

and

one or more photodetectors suitable for detecting light at the third wavelength.

17. The oximeter of claim 16, further comprising

a fourth light source emitting light of a fourth wavelength, wherein the fourth wavelength is different from each of the first, second, and third wavelengths;

and

one or more photodetectors suitable for detecting light at the fourth wavelength.

18. The oximeter of claim 10, wherein the processor is further configured to remove the contributions to the signals generated by light that never passes through fetal tissue.